Literature DB >> 10198259

Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells.

S Mori1, K Murakami-Mori, B Bonavida.   

Abstract

Prostate carcinoma cells express high levels of interleukin-6 (IL-6) and IL-6 receptor. In this study, we examined the effect of IL-6 on LNCaP human prostate carcinoma cells. IL-6 induces G1 growth arrest of LNCaP. Following IL-6 treatment of LNCaP, Western blot analysis showed that the protein levels of cyclin-dependent kinase-2 (CDK2), CDK4, and CDK6 were decreased, while accumulation of CDK inhibitor p27(Kip1) was rapidly and markedly induced. In vitro kinase assays revealed that the CDK-associated histone H1 and CDK4- and CDK6-associated pRb kinase activities were significantly inhibited in IL-6-treated LNCaP. Further, a significant amount of p27(Kip1) was co-precipitated with CDK2, CDK4 and CDK6, as detected in immunoprecipitation experiments. Thus, IL-6-induced G1 arrest appears to be due to the accumulation of p27(Kip1). In addition, IL-6-treated LNCaP cells induced neuron-like morphological changes. Since neuroendocrine differentiation is observed in most prostate carcinomas, these findings raise the possibility that IL-6 may be involved in neuroendocrine differentiation in vivo. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10198259     DOI: 10.1006/bbrc.1999.0515

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  Interleukin-6 is an autocrine growth factor in human prostate cancer.

Authors:  D Giri; M Ozen; M Ittmann
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  p27 expression in inflammatory bowel disease-associated neoplasia. Further evidence of a unique molecular pathogenesis.

Authors:  S Walsh; M Murphy; M Silverman; R Odze; D Antonioli; H Goldman; M Loda
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 3.  Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.

Authors:  Zoran Culig
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

4.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

5.  Thyroid hormone-dependent epigenetic suppression of herpes simplex virus-1 gene expression and viral replication in differentiated neuroendocrine cells.

Authors:  Robert W Figliozzi; Feng Chen; Matthew Balish; Amakoe Ajavon; S Victor Hsia
Journal:  J Neurol Sci       Date:  2014-08-20       Impact factor: 3.181

6.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.

Authors:  Hannes Steiner; Sonia Godoy-Tundidor; Hermann Rogatsch; Andreas P Berger; Dietmar Fuchs; Barbara Comuzzi; Georg Bartsch; Alfred Hobisch; Zoran Culig
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

7.  pp32 reduction induces differentiation of TSU-Pr1 cells.

Authors:  Jonathan R Brody; Shrihari S Kadkol; M Claire Hauer; Fatemeh Rajaii; Jessica Lee; Gary R Pasternack
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 8.  The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

Authors:  Bernard Paule; Stéphane Terry; Laurence Kheuang; Pascale Soyeux; Francis Vacherot; Alexandre de la Taille
Journal:  World J Urol       Date:  2007-05-31       Impact factor: 4.226

9.  Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus.

Authors:  Sophie Hillion; Soizic Garaud; Valérie Devauchelle; Anne Bordron; Christian Berthou; Pierre Youinou; Christophe Jamin
Journal:  Immunology       Date:  2007-07-03       Impact factor: 7.397

10.  Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

Authors:  T Terakawa; H Miyake; J Furukawa; S L Ettinger; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.